Amgen 2Q Revenues: $6.1 billion (+4%) 2Q Earnings: $2.3 billion (+7%) YTD Revenues: $11.6 billion (+3%) YTD Earnings: $4.6 billion (+9%) Comments: New and recently launched products including Repatha, KYPROLIS, Prolia and XGEVA, had double-digit growth, helping to offset declines for Enbrel, down 11% to $1.3 billion, Aranesp, Epogen and Neupogen, down 12%, 14% and 26% respectively. Repatha sales increased 78% to $148 million driven primarily by higher demand, offset partially by selling pri...